Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial

Takeda has developed a live-attenuated dengue tetravalent vaccine candidate (TAK-003) which has been shown to be immunogenic with acceptable reactogenicity in phase 1 trials. In agreement with World Health Organization prequalification requirements for dengue vaccines, Takeda has manufactured a lyop...

Descripción completa

Detalles Bibliográficos
Autores principales: Turner, Mark, Papadimitriou, Athanasia, Winkle, Peter, Segall, Nathan, Levin, Michael, Doust, Matthew, Johnson, Casey, Lucksinger, Gregg, Fierro, Carlos, Pickrell, Paul, Raanan, Marsha, Tricou, Vianney, Borkowski, Astrid, Wallace, Derek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644226/
https://www.ncbi.nlm.nih.gov/pubmed/32119591
http://dx.doi.org/10.1080/21645515.2020.1727697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644226/
https://www.ncbi.nlm.nih.gov/pubmed/32119591
http://dx.doi.org/10.1080/21645515.2020.1727697

Ejemplares similares